United Therapeutics progresses on expanded label for Remodulin
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 11:13AM CST
MDT: 74.08 (+0.31), UTHR: 130.22 (+2.40)
United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin
PR Newswire - Wed Dec 24, 10:26AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension.
MDT: 74.08 (+0.31), UTHR: 130.22 (+2.40)
Actelion Submits New Drug Application for Uptravi in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:35PM CST
Actelion Ltd. (ALIOF) announced the submission of a new drug application to the FDA for its pulmonary arterial hypertension candidate, Uptravi (selexipag).
ANIP: 55.24 (+1.79), UTHR: 130.22 (+2.40)
Fed's Patience Puts Bulls In A Hurry
Scott Martindale - Seeking Alpha - Tue Dec 23, 11:08AM CST
U.S. stocks found support once again last week and rallied on strong volume. Of course, the main catalyst was the FOMC policy statement on Wednesday that maintained its dovish language with a pledge of considerable time before raising the fed funds...
DEF: 38.15 (-0.96), NFO: 49.34 (-0.38), PNW: 69.59 (+1.41), UTHR: 130.22 (+2.40), ED: 66.91 (+0.90), IBB: 299.80 (+5.12), LUV: 41.66 (+0.68), IYZ: 29.52 (-0.18), LYB: 81.31 (-0.89), SPY: 207.77 (+0.02), IDU: 120.07 (+1.13), IYW: 106.52 (-0.41), IYK: 106.07 (-0.66), IYJ: 108.21 (-0.61), IYH: 144.69 (+0.58), BCR: 169.10 (-0.44), IYM: 83.15 (-0.74), IYC: 137.57 (-0.15), NXPI: 76.75 (+0.48), FUTY: 31.00 (+0.60), IYF: 91.09 (-0.41), IYE: 45.37 (-0.54), PYZ: 53.07 (+0.10), SHW: 264.55 (+1.46), KNOW: 69.79 (+0.15)
United Therapeutics Lung Drug Keeps Going And Going
at Investor's Business Daily - Fri Dec 19, 4:20PM CST
Big-cap biotech and IBD 50 stock United Therapeutics has a history of confounding expectations -- in a good way. Almost exactly a year ago, the Food and Drug Administration approved Orenitram, a pill for treating pulmonary arterial hypertension...
MDT: 74.08 (+0.31), GILD: 91.29 (+1.84), PFE: 31.42 (-0.03), UTHR: 130.22 (+2.40), NVS: 93.91 (+0.66)
Executives on the move at United Therapeutics
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:12AM CST
UTHR: 130.22 (+2.40)
United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change
PR Newswire - Wed Dec 17, 5:00AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today two senior executive promotions as well as changes to Martine Rothblatt, Ph.D's compensation program.
UTHR: 130.22 (+2.40)
Additions/deletions from Nasdaq's Q-50 Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 6:54AM CST
GLNG: 36.67 (+1.15), MXIM: 31.97 (+0.31), ODFL: 79.34 (+0.71), NUAN: 14.37 (-0.09), UTHR: 130.22 (+2.40), FSLR: 43.67 (-0.39), QQQ: 104.30 (+0.09), ALNY: 93.52 (+0.97), SCTY: 56.76 (+0.92), SHPG: 209.29 (+0.07), MPEL: 24.81 (+0.20), EXPE: 89.01 (+0.09), FFIV: 135.11 (+1.17), SSYS: 81.12 (+0.24), CAR: 64.23 (-0.25), JD: 24.61 (-0.12), SPLK: 61.49 (-0.11), MELI: 127.84 (+1.30), MEOH: 46.14 (-0.14), CREE: 32.64 (+0.08)
Quarterly Changes to the NXTQ Index
GlobeNewswire - Mon Dec 15, 6:20AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the quarterly re-ranking of the NASDAQ Q-50 Index (Nasdaq:NXTQ), which will become effective prior to market open on Monday, December 22, 2014.
MXIM: 31.97 (+0.31), ODFL: 79.34 (+0.71), EA: 48.06 (+0.23), UTHR: 130.22 (+2.40), ALNY: 93.52 (+0.97), SCTY: 56.76 (+0.92), SHPG: 209.29 (+0.07), SSYS: 81.12 (+0.24), FFIV: 135.11 (+1.17), MPEL: 24.81 (+0.20), AAL: 51.43 (+1.22), CAR: 64.23 (-0.25), NWS: 14.92 (-0.07), MEOH: 46.14 (-0.14), CREE: 32.64 (+0.08), GLNG: 36.67 (+1.15), NUAN: 14.37 (-0.09), FSLR: 43.67 (-0.39), LRCX: 81.13 (-0.44), EXPE: 89.01 (+0.09), SPLK: 61.49 (-0.11), JD: 24.61 (-0.12), MELI: 127.84 (+1.30), NDAQ: 48.74 (-0.40)
United Therapeutics: Will It Pass Peers In 2015?
at Investor's Business Daily - Fri Dec 12, 5:11PM CST
Biomed company United Therapeutics is in a strong industry group, and that's a problem. United Therapeutics' (UTHR) three-year earnings growth rate is 26%, good enough for an EPS Rating of 89. However, in a leading group, "good enough" isn't good...
BIIB: 340.89 (+5.13), UTHR: 130.22 (+2.40), ALXN: 181.96 (+3.09), TEVA: 57.09 (+0.33), CELG: 109.60 (+3.48)
Can United Therapeutics find a remedy for recent resistance?
at Investor's Business Daily - Thu Dec 11, 10:48AM CST
Today we'll look at United Therapeutics (UTHR), which develops therapies to treat pulmonary arterial hypertension, cancer and some of the most complicated viral diseases. Key Fundamentals After a sharp decline in earnings growth for several quarters,...
UTHR: 130.22 (+2.40)
Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Thu Dec 11, 7:05AM CST
United Therapeutics (NASDAQ:UTHR) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $131.51 on volume of 653,000 shares, below average daily volume of 670,000. Based on a current price of $131.51, United Therapeutics is currently 3.7% above its average consensus analyst price target of $126.62. The stock should discover initial support at its 50-day moving average (MA) of $128.48 and subsequent support at its 200-day MA of $106.56.
UTHR: 130.22 (+2.40)
Stocks Fall To Session Lows: GoPro Gives Up More Ground
at Investor's Business Daily - Mon Dec 08, 12:25PM CST
Stocks were near session lows in early afternoon trading as oil prices fell hard again. The Nasdaq lost 0.5%, the S&P 500 fell 0.4% and the Dow Jones industrial average gave up 0.4% also. Nasdaq and NYSE volume was tracking slightly higher than...
AMBA: 52.05 (+0.72), GPRO: 66.41 (+4.87), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), UTHR: 130.22 (+2.40), MCD: 93.83 (-0.39), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.46 (unch), GILD: 91.29 (+1.84), UTHR: 130.22 (+2.40), GSK: 42.85 (+0.11), ARNA: 3.57 (-0.01)
Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 2:10PM CST
Actelion Ltd. (ALIOF) submitted a centralized marketing authorization application to the European Medicines Agency for its PAH candidate, Uptravi (selexipag).
BIIB: 340.89 (+5.13), UTHR: 130.22 (+2.40)
Stock Market Today: Top Biotech Is Near Buy Point
at Investor's Business Daily - Wed Nov 26, 4:40PM CST
Many leading stocks have risen out of buying range since a new market uptrend began last month, but a number are still working on bases. United Therapeutics (UTHR), which develops treatments for cardiovascular and infectious diseases as well as for...
UTHR: 130.22 (+2.40), GIII: 99.53 (+1.82), CAR: 64.23 (-0.25), CP: 194.85 (-0.13)
United Therapeutics Earnings In Retrospect: Down 3.9% in the Last 20 Days (UTHR)
Comtex SmarTrend(R) - Mon Nov 17, 3:24PM CST
20 days ago, on October 28th, 2014, United Therapeutics (NASDAQ:UTHR) reported its earnings. Analysts, on average, expected earnings of $2.75 per share on sales of $335.1 million. The company actually reported EPS of $3.91 on sales of $330.0 million, beating EPS estimates by $1.16 and missing revenue estimates by $5.2 million. Since the company's report, shares of United Therapeutics have fallen from $130.49 to $125.43, representing a loss of 3.9% in the past 20 days.
UTHR: 130.22 (+2.40)
United Therapeutics appoints Professor Katherine J. Klein to board
M2 - Thu Nov 13, 7:08AM CST
Biotechnology company United Therapeutics (NasdaqGS:UTHR) stated on Thursday that Professor Katherine J. Klein, PhD has been elected as an independent director to its board of directors with effect from 11 November 2014.
UTHR: 130.22 (+2.40)
Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors
PR Newswire - Thu Nov 13, 5:00AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today the appointment of Professor Katherine J. Klein, Ph.D., of The Wharton School of the University of Pennsylvania to its Board of Directors as an independent director. The appointment is effective as of November 11, 2014.
UTHR: 130.22 (+2.40), SCHW: 30.67 (+0.01)
United Therapeutics Earnings In Retrospect: Down 4.8% in the Last 13 Days (UTHR)
Comtex SmarTrend(R) - Mon Nov 10, 12:57PM CST
When United Therapeutics (NASDAQ:UTHR) reported earnings a week ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $2.75 on sales of $335.1 million. United Therapeutics actually reported earnings of $3.91 per share on sales of $330.0 million, beating EPS estimates by $1.16 and missing revenue estimates by $5.2 million. Shares of United Therapeutics have slipped from $130.49 to $124.21, representing a loss of 4.8%, since the company reported earnings 13 days ago.
UTHR: 130.22 (+2.40)